In patients with severe asthma, treatment with salmeterol or formoterol was associated with similar significant improvement in morning peak expiratory flow (PEF), according to a recent report. Previous reports indicate that treatment with salmeterol or formoterol, both long-acting beta2-agonists, provides better asthma control than regular treatment with albuterol or placebo.
However, no clinical trials have ever compared salmeterol with formoterol as a treatment for patients with severe asthma. Dr. Julia A. Nightingale and colleagues, from the National Heart and Lung Institute in London, performed a randomized, placebo-controlled, crossover study of the two medications in 42 nonsmoking patients with severe asthma.
Each treatment period lasted 4 weeks with inhaled formoterol given at a dose of 12 g twice daily and salmeterol given at a dose of 50 g twice daily.
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!